MovDisordV3, Main, Exploration, bibRecord, 000922

Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial

Identifieur interne : 000922 ( Main/Exploration ); précédent : 000921; suivant : 000923

Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial

Auteurs : Radu Constantinescu [États-Unis] ; Jordan Elm [États-Unis] ; Peggy Auinger [États-Unis] ; Saloni Sharma [États-Unis] ; Erika F. Augustine [États-Unis] ; Laith Khadim [États-Unis] ; Karl Kieburtz [États-Unis]

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2013.

RBID : PMC:4375545

Descripteurs français

Wicri :
- geographic : États-Unis.

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Cohort Studies, Double-Blind Method, Female, Humans, Incidence, Male, Melanoma (chemically induced), Melanoma (epidemiology), Middle Aged, National Institutes of Health (U.S.), Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Selegiline (therapeutic use), Skin Neoplasms (epidemiology), United States, Young Adult.
MESH :
- chemical , therapeutic use : Neuroprotective Agents, Selegiline.
- geographic : United States.
- chemically induced : Melanoma.
- drug therapy : Parkinson Disease.
- epidemiology : Melanoma, Parkinson Disease, Skin Neoplasms.
- Adult, Aged, Aged, 80 and over, Cohort Studies, Double-Blind Method, Female, Humans, Incidence, Male, Middle Aged, National Institutes of Health (U.S.), Young Adult.

Abstract

Background

The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.

Methods

Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, using the expected incidence rates and the number of person-years.

Results

A total of 618 females and 1119 males were followed for 6452 person-years; 19 new melanoma cases were observed. The expected number was 5.29. The standardized event ratio compared to the general population was 3.6 (95% confidence interval, 2.2-5.6).

Conclusions

The risk for developing melanoma was higher than expected in the NET-PD LS-1 cohort and was similar to the risk reported in earlier comparable clinical trial cohorts. Dermatologic screening may be useful in Parkinson's disease to identify melanoma at an early stage.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375545

DOI: 10.1002/mds.25734
PubMed: 24323565
PubMed Central: 4375545

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial</title>
<author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sharma, Saloni" sort="Sharma, Saloni" uniqKey="Sharma S" first="Saloni" last="Sharma">Saloni Sharma</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Augustine, Erika F" sort="Augustine, Erika F" uniqKey="Augustine E" first="Erika F." last="Augustine">Erika F. Augustine</name>
<affiliation wicri:level="2"><nlm:aff id="A3">Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khadim, Laith" sort="Khadim, Laith" uniqKey="Khadim L" first="Laith" last="Khadim">Laith Khadim</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24323565</idno>
<idno type="pmc">4375545</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375545</idno>
<idno type="RBID">PMC:4375545</idno>
<idno type="doi">10.1002/mds.25734</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000374</idno>
<idno type="wicri:Area/Pmc/Curation">000374</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000106</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000663</idno>
<idno type="wicri:Area/PubMed/Curation">000663</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000532</idno>
<idno type="wicri:Area/Ncbi/Merge">003E34</idno>
<idno type="wicri:Area/Ncbi/Curation">003E34</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003E34</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Constantinescu R:malignant:melanoma:in</idno>
<idno type="wicri:Area/Main/Merge">000922</idno>
<idno type="wicri:Area/Main/Curation">000922</idno>
<idno type="wicri:Area/Main/Exploration">000922</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial</title>
<author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sharma, Saloni" sort="Sharma, Saloni" uniqKey="Sharma S" first="Saloni" last="Sharma">Saloni Sharma</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Augustine, Erika F" sort="Augustine, Erika F" uniqKey="Augustine E" first="Erika F." last="Augustine">Erika F. Augustine</name>
<affiliation wicri:level="2"><nlm:aff id="A3">Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khadim, Laith" sort="Khadim, Laith" uniqKey="Khadim L" first="Laith" last="Khadim">Laith Khadim</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cohort Studies</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Melanoma (chemically induced)</term>
<term>Melanoma (epidemiology)</term>
<term>Middle Aged</term>
<term>National Institutes of Health (U.S.)</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Selegiline (therapeutic use)</term>
<term>Skin Neoplasms (epidemiology)</term>
<term>United States</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Melanoma</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Melanoma</term>
<term>Parkinson Disease</term>
<term>Skin Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cohort Studies</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>National Institutes of Health (U.S.)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.</p>
</sec>
<sec id="S2"><title>Methods</title>
<p id="P2">Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, using the expected incidence rates and the number of person-years.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">A total of 618 females and 1119 males were followed for 6452 person-years; 19 new melanoma cases were observed. The expected number was 5.29. The standardized event ratio compared to the general population was 3.6 (95% confidence interval, 2.2-5.6).</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">The risk for developing melanoma was higher than expected in the NET-PD LS-1 cohort and was similar to the risk reported in earlier comparable clinical trial cohorts. Dermatologic screening may be useful in Parkinson's disease to identify melanoma at an early stage.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Sud</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name>
</region>
<name sortKey="Augustine, Erika F" sort="Augustine, Erika F" uniqKey="Augustine E" first="Erika F." last="Augustine">Erika F. Augustine</name>
<name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name>
<name sortKey="Khadim, Laith" sort="Khadim, Laith" uniqKey="Khadim L" first="Laith" last="Khadim">Laith Khadim</name>
<name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<name sortKey="Sharma, Saloni" sort="Sharma, Saloni" uniqKey="Sharma S" first="Saloni" last="Sharma">Saloni Sharma</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000922 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000922 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:4375545
   |texte=   Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24323565" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial

Malignant Melanoma in Early-Treated Parkinson's Disease: The NET-PD Trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.